📝 CURRICULUM VITAE – ZENGBIN WANG, PhD
🎓 EARLY ACADEMIC PURSUITS
Zengbin Wang began his academic journey with a strong foundation in medical sciences. He earned his Master of Medicine in Immunology from Fujian Medical University (Sep 2017 – Jun 2020), where he cultivated his expertise in immune responses and disease mechanisms. Subsequently, he pursued and completed his Doctor of Medicine (MD) in Clinical Laboratory Diagnostics at the same institution (Sep 2020 – Jun 2023). During his doctoral studies, he focused on laboratory-based diagnostics, exploring molecular pathways and immune responses in various diseases, laying the groundwork for his future research contributions.
👩🏫 PROFESSIONAL ENDEAVORS
Since September 4, 2023, Zengbin Wang has been serving as a lecturer at the Department of Immunology, School of Basic Medical Sciences, Fujian Medical University. In this role, he actively contributes to both academic instruction and research mentorship. His teaching focuses on immunology, molecular diagnostics, and clinical laboratory techniques. His position also involves supervising student research projects, fostering scientific inquiry, and guiding the next generation of medical scientists.
🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CHEMOTHERAPY
Zengbin Wang’s research interests span multiple fields in oncology and immunology, with a primary focus on:
-
DILI (Drug-Induced Liver Injury): Investigating the molecular mechanisms of hepatotoxicity caused by pharmaceuticals.
-
Arsenic-Induced Lung Cancer: Exploring the oncogenic pathways and cellular responses triggered by arsenic exposure.
-
Signal Regulation and Autophagy: Studying the complex signaling cascades and autophagic processes in cancer progression.
-
SUMOylation and Acetylation: Delving into post-translational modifications and their impact on tumorigenesis.
-
Tumor Immunity: Examining immune responses in the tumor microenvironment, with a focus on immune evasion and therapeutic targeting.
📚 IMPACT AND INFLUENCE
In the past three years, Dr. Wang has demonstrated remarkable productivity and influence in his field, having published 13 SCI-indexed papers as the first author in prestigious journals, including:
-
🧬 Science Signaling
-
🧫 Cellular Oncology
-
🔬 Cell Communication and Signaling
-
💊 Biomedicine & Pharmacotherapy
-
☣️ Toxicology
-
🔗 Communications Biology
-
⚕️ Toxicology and Applied Pharmacology
His research has contributed to advancing the understanding of cancer biology, autophagy, and tumor immunity, providing valuable insights into the molecular underpinnings of disease progression and potential therapeutic interventions.
🔥 ACADEMIC CITES AND FUNDING ACHIEVEMENTS
Dr. Wang’s research accomplishments are further underscored by his involvement in several high-profile projects, including:
-
Startup Fund for Scientific Research of Fujian Medical University (2019QH2022) – Principal Investigator.
-
National Natural Science Foundation of China (82403155) – Lead Investigator.
-
Key Project of Fujian Provincial Natural Science Foundation (2022J02039) – Second person in charge.
-
National Natural Science Foundation of China (82173167) – Key participant.
These projects reflect his ability to secure competitive funding, demonstrating his expertise in developing and leading impactful research initiatives.
🌍 LEGACY AND FUTURE CONTRIBUTIONS
Dr. Zengbin Wang's legacy is marked by his prolific scientific output, impactful discoveries, and commitment to advancing oncology and immunology research. His work on SUMOylation, acetylation, and tumor immunity holds significant potential for influencing cancer treatment strategies, particularly in the development of novel immunotherapies and diagnostic tools.
Looking forward, Dr. Wang aims to:
-
Expand his research on post-translational modifications and their role in tumor progression.
-
Collaborate with international researchers to broaden the clinical applications of his findings.
-
Mentor the next generation of scientists, fostering innovation and scientific excellence in oncology and immunology.
🛡️ CONCLUSION
Dr. Zengbin Wang is an influential figure in oncology, immunology, and molecular diagnostics, recognized for his substantial research output, leadership in major projects, and dedication to scientific advancement. With a proven track record of impactful publications and research funding, he is poised to make significant contributions to cancer research and therapeutic development, enhancing the scientific community's understanding of disease mechanisms and treatment approaches.